Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - stavudine 30mg - capsule - 30 mg - active: stavudine 30mg excipient: gelatin lactose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - zerit (stavudine) is indicated for the treatment of hiv infection in adults and paediatric patients, in combination with other anti-retrovirals.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - stavudine 40mg - capsule - 40 mg - active: stavudine 40mg excipient: gelatin lactose lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - zerit (stavudine) is indicated for the treatment of hiv infection in adults and paediatric patients, in combination with other anti-retrovirals.

Izrael - angličtina - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - powder for concentrate for solution for infusion - abatacept 250 mg - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists. polyarticular juvenile idiopathic arthritis: orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).orencia is indicated for the prophylaxis of acute graft versus host disease (agvhd), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 6 years of age or older undergoing hematopoietic stem cell transplantation (hsct) from a matched or 1 allele-mismatched unrelated-donor.

Izrael - angličtina - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - solution for injection - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.orencia is indicated for the treatment of adult patients with active psoriatic arthritis (psa).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - paclitaxel 6 mg/ml - concentrate for infusion - 6 mg/ml - active: paclitaxel 6 mg/ml excipient: ethanol polyoxyl 35 castor oil

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) - injection (depot) - 25 mg/ml - active: fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) excipient: benzyl alcohol nitrogen sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 100 mg/ml - injection (depot) - 100 mg/ml - active: fluphenazine decanoate 100 mg/ml excipient: benzyl alcohol sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 262.5mg;  ;   - powder for injection - 250 mg - active: abatacept 262.5mg     excipient: hydrochloric acid maltose monobasic sodium phosphate dihydrate sodium chloride sodium hydroxide - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progression of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. orencia is indicated for reducing signs and symptoms in paediatric patients 6 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). orencia may be used concomitantly with methotrexate (mtx). (there is no clinical trial data for the use of orencia subcutaneous formulation in children, therefore its use in children cannot be recommended.) orencia should not be administered concurrently with other biological dmards (eg, tnf inhibitors, rituximab, or anakinra).

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - abatacept 125.875mg equivalent to abatacept 125mg/ml;  ;   - solution for injection - 125 mg - active: abatacept 125.875mg equivalent to abatacept 125mg/ml     excipient: dibasic sodium phosphate monobasic sodium phosphate nitrogen poloxamer 188 sucrose water for injection - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease modifying anti-rheumatic drugs (dmards), such as methotrexate or tumour necrosis factor (tnf) blocking agents. a reduction in the progress of joint damage and improvement in physical function have been demonstrated during combination treatment with orencia and methotrexate. orencia in combination with methotrexate is also indicated in the treatment of severe, active and progressive rheumatoid arthiritis in adults not previously treated with methotrexate. orencia should not be administered concurrently with other dmards (eg. tnf inhibitors, rituximab or anakinra).

Spojené kráľovstvo - angličtina - myHealthbox

bristol-myers squibb pharma eeig - nivolumab - concentrate for solution for infusion - 10 mg/ml - antineoplastic agents, monoclonal antibodies - as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults